Development of A Cross-Border Regulatory Harmonization Model for African Pharmaceutical Markets: The ARCH-Model Framework

The fragmentation of pharmaceutical regulatory systems across Africa's 55 nations constitutes one of the most consequential structural barriers to universal health coverage on the continent, generating an estimated USD 2.5 to 3.8 billion in annual avoidable costs through duplicative regulatory assessment processes, delayed medicine registration, proliferation of substandard and falsified medicines, and procurement inefficiency attributable to limited competition in fragmented national markets. Each African country operates an independent national medicines regulatory authority whose technical capacity, dossier format requirements, quality standards, and postmarket surveillance architecture diverge substantially from those of neighboring jurisdictions, collectively requiring pharmaceutical manufacturers seeking pan-African market access to complete 55 separate registration processes with a combined completion timeline of 15 to 25 years and total compliance costs exceeding USD 100 million per product. This regulatory fragmentation directly undermines access to quality-assured essential medicines for Africa's 1.4 billion population and systematically disadvantages African patients relative to counterparts in regulatory harmonization zones where centralized or mutually recognized registration enables continental market access within 12 to 18 months. This paper presents the African Regulatory Convergence and Harmonization Model (ARCH-Model), a four-phase continental regulatory integration framework designed to achieve continental-scale harmonization of pharmaceutical regulatory systems across Africa's Regional Economic Communities within a 15 to 25-year implementation horizon. The four phases are: Phase 1 National Foundation Building, Phase 2 REC-Level Technical Harmonization, Phase 3 Mutual Recognition Architecture, and Phase 4 AMA Continental Governance. The model integrates evidence from WHO regulatory system strengthening initiatives, the African Medicines Regulatory Harmonization programme, the African Medicines Agency treaty, ASEAN and EU harmonization precedents, industrial safety governance and environmental risk management frameworks, supply chain governance, digital platform architecture, healthcare infrastructure capacity assessment, data governance design, and agricultural development policy alignment. The paper specifies phase deliverables, governance standards, REC capacity profiles, digital infrastructure architecture (PARIS), multi-source financing mechanisms, stakeholder engagement frameworks, and an economic analysis demonstrating net present value of USD 24 to 60 billion over 25 years against total investment of USD 1.5 to 2.8 billion.

Authors

Institutions

Publication Details

Journal
INTERNATIONAL JOURNAL OF HEALTH AND PHARMACEUTICAL RESEARCH
Published
2026-11-17
DOI
https://doi.org/10.56201/ijhpr.v9.no5.2024.pg148.186
Citations
21
Primary Topic
Healthcare Regulation
Type
article
Field-Weighted Citation Impact
58.53
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development of A Cross-Border Regulatory Harmonization Model for African Pharmaceutical Markets: The ARCH-Model Framework

Felix Ikechukwu Eze
21 citations
INTERNATIONAL JOURNAL OF HEALTH AND PHARMACEUTICAL RESEARCH
Healthcare Regulation
58.53
article

Development of A Cross-Border Regulatory Harmonization Model for African Pharmaceutical Markets: The ARCH-Model Framework

Felix Ikechukwu Eze
article en
21 citations

Abstract

The fragmentation of pharmaceutical regulatory systems across Africa's 55 nations constitutes one of the most consequential structural barriers to universal health coverage on the continent, generating an estimated USD 2.5 to 3.8 billion in annual avoidable costs through duplicative regulatory assessment processes, delayed medicine registration, proliferation of substandard and falsified medicines, and procurement inefficiency attributable to limited competition in fragmented national markets. Each African country operates an independent national medicines regulatory authority whose technical capacity, dossier format requirements, quality standards, and postmarket surveillance architecture diverge substantially from those of neighboring jurisdictions, collectively requiring pharmaceutical manufacturers seeking pan-African market access to complete 55 separate registration processes with a combined completion timeline of 15 to 25 years and total compliance costs exceeding USD 100 million per product. This regulatory fragmentation directly undermines access to quality-assured essential medicines for Africa's 1.4 billion population and systematically disadvantages African patients relative to counterparts in regulatory harmonization zones where centralized or mutually recognized registration enables continental market access within 12 to 18 months. This paper presents the African Regulatory Convergence and Harmonization Model (ARCH-Model), a four-phase continental regulatory integration framework designed to achieve continental-scale harmonization of pharmaceutical regulatory systems across Africa's Regional Economic Communities within a 15 to 25-year implementation horizon. The four phases are: Phase 1 National Foundation Building, Phase 2 REC-Level Technical Harmonization, Phase 3 Mutual Recognition Architecture, and Phase 4 AMA Continental Governance. The model integrates evidence from WHO regulatory system strengthening initiatives, the African Medicines Regulatory Harmonization programme, the African Medicines Agency treaty, ASEAN and EU harmonization precedents, industrial safety governance and environmental risk management frameworks, supply chain governance, digital platform architecture, healthcare infrastructure capacity assessment, data governance design, and agricultural development policy alignment. The paper specifies phase deliverables, governance standards, REC capacity profiles, digital infrastructure architecture (PARIS), multi-source financing mechanisms, stakeholder engagement frameworks, and an economic analysis demonstrating net present value of USD 24 to 60 billion over 25 years against total investment of USD 1.5 to 2.8 billion.

INTERNATIONAL JOURNAL OF HEALTH AND PHARMACEUTICAL RESEARCH
Syracuse University (US)
Good health and well-being
Openalex Percentile: Top 0%
Healthcare Regulation
58.53
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon